Danaher (DHR) Stock Forecast & Price Target

Danaher is supported by a broadening growth recovery, led by its market-leading bioprocessing franchise, where resilient consumables demand, improving equipment orders, and de-risked resin timing should help results recover from the Q2 miss and support the long-term high-single-digit thesis. Life Sciences also strengthened with about 5.5% growth and 27.1% adjusted operating margins, while Diagnostics appears to have troughed as China reimbursement guidance and a moderate flu season reduce downside risk and a new multiplexed respiratory test expands share opportunity. The company’s quality is reinforced by $6.27B of revenue, $1.94 adjusted EPS, and $1.3B of free cash flow in the quarter, showing strong execution and cash generation.

Danaher is facing a fundamentally weak setup because its Life Sciences business has posted sales declines for the past two years, with instrument demand still declining and only a cautious low-mid single digit 2H growth outlook versus 5.5% in Q2. Its bioprocess equipment recovery has not materialized despite reshoring commentary, China diagnostics remain a drag with sales now under $1B of annual company sales, and several recent Life Sciences acquisitions have failed to meet expectations. Those pressures raise the risk of multiple compression, as investors may stop rewarding the company with a premium valuation if the growth rebound keeps disappointing.